Evidence map›Paper›PMID 21689062›Full record

ArticleTissue engineering. Part A2011

Controlling the fibroblastic differentiation of mesenchymal stem cells via the combination of fibrous scaffolds and connective tissue growth factor.

Zhixiang Tong, Shilpa Sant, Ali Khademhosseini, Xinqiao Jia

Open access · greenAbstract read
In one paragraph

Article in Tissue engineering. Part A, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Zhixiang TongDepartment of Materials Science and Engineering, Delaware Biotechnology Institute, University of Delaware, Newark, Delaware 19716, USA.
Shilpa Sant
Ali Khademhosseini
Xinqiao Jia
Harvard–MIT Division of Health Sciences and Technology · USUniversity of Delaware · US

Funding

Microengineered Osteons for Bone Tissue EngineeringR01AR057837 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YANG, YUNZHI · 2010 to 2018
$5.1M
3D combinatorial microenvironments for effective cell based therapyR01HL099073 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI, LIAO, RONGLIH · 2010 to 2013
$2.6M
Microengineered environments for epithelial-mesenchymal interactions (SysCODE 7RL1DE019024 · NIDCR · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI · 2007 to 2011
$1.9M
Tissue Engineering of Vocal Fold Lamina PropriaR01DC008965 · NIDCD · UNIVERSITY OF DELAWARE · PI JIA, XINQIAO · 2007 to 2011
$1.9M
High-Throughput Analysis of Cell Response to Chemical LibrariesR21EB009196 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI · 2009 to 2010
$485k
ENGINEERING OF THE MURINE EMBRYONIC STEM CELL MICROENVIRONMENTR21EB007249 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI · 2007 to 2008
$458k
NHLBI NIH HHS HL099073NIAMS NIH HHS AR057837NIBIB NIH HHS EB007249NIBIB NIH HHS EB009196NIDCD NIH HHS R01 DC008965NIDCR NIH HHS DE019024PHS HHS R01 008965
6 · The paper itself

Abstract

Controlled differentiation of multi-potent mesenchymal stem cells (MSCs) into vocal fold-specific, fibroblast-like cells in vitro is an attractive strategy for vocal fold repair and regeneration. The goal of the current study was to define experimental parameters that can be used to control the initial fibroblastic differentiation of MSCs in vitro. To this end, connective tissue growth factor (CTGF) and micro-structured, fibrous scaffolds based on poly(glycerol sebacate) (PGS) and poly(ɛ-caprolactone) (PCL) were used to create a three-dimensional, connective tissue-like microenvironment. MSCs readily attached to and elongated along the microfibers, adopting a spindle-shaped morphology during the initial 3 days of preculture in an MSC maintenance medium. The cell-laden scaffolds were subsequently cultivated in a conditioned medium containing CTGF and ascorbic acids for up to 21 days. Cell morphology, proliferation, and differentiation were analyzed collectively by quantitative PCR analyses, and biochemical and immunocytochemical assays. F-actin staining showed that MSCs maintained their fibroblastic morphology during the 3 weeks of culture. The addition of CTGF to the constructs resulted in an enhanced cell proliferation, elevated expression of fibroblast-specific protein-1, and decreased expression of mesenchymal surface epitopes without markedly triggering chondrogenesis, osteogenesis, adipogenesis, or apoptosis. At the mRNA level, CTGF supplement resulted in a decreased expression of collagen I and tissue inhibitor of metalloproteinase 1, but an increased expression of decorin and hyaluronic acid synthesase 3. At the protein level, collagen I, collagen III, sulfated glycosaminoglycan, and elastin productivity was higher in the conditioned PGS-PCL culture than in the normal culture. These findings collectively demonstrate that the fibrous mesh, when combined with defined biochemical cues, is capable of fostering MSC fibroblastic differentiation in vitro.

Indexed as

Cell DifferentiationCell ProliferationCells, CulturedCell SurvivalConnective Tissue Growth FactorFibroblastsHumansImmunohistochemistryMesenchymal Stem CellsTissue EngineeringTissue ScaffoldsConnective Tissue Growth Factor

Identifiers

PMID21689062
PMCPMC3204202
OpenAlexW1999062030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.